Abstract
In connection with the threat of a worsening epidemic situation in tuberculosis in Russia and in the world, the growth of drug resistance to anti-tuberculosis drugs, it is advisable to assess the dynamics of financing of anti-tuberculosis activities, as well as the state of fixed assets of medical organizations providing TB care from the point of their readiness for these challenges. Aim. To study the financing of anti-tuberculosis activities and the state of fixed assets of organizations providing medical care to patients with tuberculosis. Methods. The authors studied these forms of financial monitoring for 2016-2021. We calculated indicators of per capita financing, taking into account inflation, the structure of financing, the state of fixed assets according to official methods. Results. The maximum per capita funding for tuberculosis control activities was observed in 2019; during the years of the COVID-19 pandemic, its level was approximately the same as in 2018. The share of funding for the purchase of innovative anti-TB drugs increased from 0.3% to 3.2%, as well as the cost of abacillation of one patient with MDR-TB, which is associated with the introduction of new clinical guidelines and the growth of drug resistance to fluoroquinolones. The COVID-19 pandemic led to a decrease in funds spent on training and supervision, which was offset by the introduction of distance learning technologies. Depreciation of fixed assets was consistently high; funds for their renewal ensured their stable condition with a slight obsolescence of buildings and structures and equipment renewal. Conclusion. The challenges that the TB care system may face in the future will not allow working with its existing worn-out structure in the old way; it is necessary either to increase funds for the renewal of fixed assets, or to look for new methods of work in the conditions of depreciated fixed assets, redistributing funds for the renewal, first of all, of equipment and tools to work in the context of the widespread introduction of hospital-replacing technologies.